STOCKWATCH: J&J points to medtech dip, Novartis lobs MS grenade to Teva
This article was originally published in Scrip
Executive Summary
Second-quarter earnings season kicked off properly this week with the world's largest healthcare company, Johnson & Johnson, reporting (scripintelligence.com, 16 July 2013). The healthcare conglomerate commonly known as J&J has a market capitalisation of nearly $260bn and is so diverse that it provides a window into other pure-play pharmaceutical, consumer, medical device and diagnostic companies, as well as a number of specific drugs, the revenues on which, much smaller companies are dependent.
You may also be interested in...
Stockwatch: Earnings Season Appears Not At Home To Brexit
On the morning of the vote by the UK to leave the EU, I speculated firstly that the ensuing currency swings would come too late to impact the imminent second-quarter pharma earnings announcements but secondly, that they could have an effect on the guidance of companies for the rest of the year. In the opening week of earnings season I am currently one for two in the prediction stakes as the effects of Brexit barely figured in either the results or the full-year guidance.
Stockwatch: The Lexicon Of Biotech Survival
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
Need a specific report? 1000+ reports available
Buy Reports